Day One Biopharmaceuticals (DAWN)
(Delayed Data from NSDQ)
$14.23 USD
+0.82 (6.11%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $14.25 +0.02 (0.14%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Day One Biopharmaceuticals, Inc. (DAWN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$36.00 | $44.00 | $24.00 | 168.46% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Day One Biopharmaceuticals, Inc. comes to $36.00. The forecasts range from a low of $24.00 to a high of $44.00. The average price target represents an increase of 168.46% from the last closing price of $13.41.
Analyst Price Targets (8 )
Broker Rating
Day One Biopharmaceuticals, Inc. currently has an average brokerage recommendation (ABR) of 1.30 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.60 a month ago based on 10 recommendations.
Of the 10 recommendations deriving the current ABR, eight are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 80% and 10% of all recommendations. A month ago, Strong Buy made up 70%, while Buy represented 10%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/DAWN.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 7 | 7 | 7 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.30 | 1.30 | 1.60 | 1.60 | 1.60 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/1/2024 | Cowen & Co. | Marc Frahm | Strong Buy | Strong Buy |
7/31/2024 | Needham & Company | Ami Fadia | Moderate Buy | Moderate Buy |
7/26/2024 | H.C. Wainwright & Co. | Andres Y Maldonado | Strong Buy | Strong Buy |
7/25/2024 | Wedbush Securities | Robert Driscoll | Strong Buy | Strong Buy |
7/25/2024 | Capital One Securities | Naureen Quibria | Strong Buy | Strong Buy |
7/8/2024 | Piper Sandler | Joseph M Catanzaro | Strong Buy | Strong Buy |
2/27/2024 | Goldman Sachs | Andrea Tan | Strong Buy | Strong Buy |
2/27/2024 | Not Identified | Not Identified | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.30 |
ABR (Last week) | 1.30 |
# of Recs in ABR | 10 |
Average Target Price | $36.00 |
LT Growth Rate | 24.80% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 80 of 253 |
Current Quarter EPS Est: | -0.22 |